ABCL - AbCellera and Tachyon Therapeutics ink drug discovery and development collaboration

AbCellera (NASDAQ:ABCL) and Tachyon Therapeutics announce a collaboration to facilitate the discovery and development of a therapeutic antibody targeting LEFTY1 in advanced cancers. Under the terms of the agreement, AbCellera is eligible to receive milestone payments and royalties on products that are derived from its antibody discovery platform. In addition, AbCellera has the option to invest in preclinical and clinical development in exchange for an increased share of product sales. Shares up more than 2% premarket. AbCellera and Angios GmbH had inked a multi-year, multi-target collaboration for the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye, in May.

For further details see:

AbCellera and Tachyon Therapeutics ink drug discovery and development collaboration